Positive Phase I results for small molecule complement inhibitor
Biopharmaceutical company Annexon has reported promising results from its Phase I single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502. ANX1502 is a first-in-kind oral, selective small molecule inhibitor that targets the active form of C1s responsible for propagating classical pathway… Read More